News

European Commission Approves Roche’S Columvi As The First Bispecific Antibody For Diffuse Large B-Cell Lymphoma After Initial Therapy
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of ...